Month: November 2016

Creative Medical Technology Holdings Announces Creation of Amniotic Fluid Stem Cell Focused Subsidiary AmnioStem LLC

Clinical Stage Stem Cell Therapeutics Company Expands Regenerative Medicine Portfolio to ‘Off-the-Shelf’ Allogeneic Stem Cell Products PHOENIX, Nov. 16, 2016 /PRNewswire/ — Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of a wholly-owned subsidiary, AmnioStem LLC, focused on the development of therapeutic products derived from amniotic fluid stem cells. These stem cells are subject …

Creative Medical Technology Holdings Announces Creation of Amniotic Fluid Stem Cell Focused Subsidiary AmnioStem LLC Read More »

Creative Medical Technologies Receives Exclusive License to Key Amniotic Fluid Stem Cell Patent from University of California System

Patent Rights Cover Multipotent Amniotic Fetal Stem Cells PHOENIX, Nov. 2, 2016 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced today signing of an exclusive license agreement with the University of California System to commercialize and develop a novel type of amniotic fluid derived stem cell as disclosed in issued US Patent No. 7,569,385. …

Creative Medical Technologies Receives Exclusive License to Key Amniotic Fluid Stem Cell Patent from University of California System Read More »

Creative Medical Technology Holdings, Inc. Recruits Internationally Renowned Urologic Surgery Pioneer Dr. Alexander Gershman to Scientific Advisory Board

Clinical Stage Company Developing Stem Cell Therapy for Treatment-Refractory Erectile Dysfunction Recruits “Doctor to the Stars” PHOENIX, Nov. 1, 2016 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today appointment of Alexander Gershman, MD, Ph.D to the company’s Scientific Advisory Board. Dr. Gershman is an internationally-renowned opinion leader in urological surgery having pioneered …

Creative Medical Technology Holdings, Inc. Recruits Internationally Renowned Urologic Surgery Pioneer Dr. Alexander Gershman to Scientific Advisory Board Read More »